ISFIYA, Israel and BOSTON, Dec. 5,
2017 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or
"Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical
diagnostics company engaged in the development of
C-Scan®, an ingestible capsule for preparation-free,
colorectal cancer screening, today announced it has entered the
next phase of its manufacturing collaboration with GE Healthcare
("GE"). The new phase involves GE final assembly, packaging
and shipping of C-Scan capsules initially to support the Company's
US pilot trial expected in 1H2018. Check-Cap will supply GE with
supporting calibration and final assembly methodology and
equipment.
Bill Densel, CEO of Check-cap
commented, "We are very pleased to advance our collaboration with
GE, moving forward with the initiation of this next phase that
prepares us for our C-Scan capsule needs, beginning with our
planned US pilot trial in 1H2018. Planning and other activities are
also underway for our European post approval study, which is also
expected in 1H2018."
About Check-Cap
Check-Cap is a clinical-stage medical
diagnostics company developing C-Scan®, the first capsule-based
system for preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless
communication technologies, the capsule generates information on
the contours of the inside of the colon as it passes naturally.
This information is used to create a 3D map of the colon, which
allows physicians to look for polyps and other abnormalities.
Designed to improve the patient experience and increase the
willingness of individuals to participate in recommended colorectal
cancer screening, C-Scan removes many frequently-cited barriers,
such as laxative bowel preparation, invasiveness and sedation. The
C-Scan system is currently not cleared for marketing in any
jurisdiction.
Legal Notice Regarding Forward-Looking Statements
This
press release contains "forward-looking statements." Words such as
"may," "should," "could," "would," "predicts," "potential,"
"continue," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," and similar expressions, as well as
statements in future tense, often signify forward-looking
statements. Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate
indications of when such performance or results will be achieved.
Forward-looking statements are based on information that the
Company has when those statements are made or management's good
faith belief as of that time with respect to future events, and are
subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in
or suggested by the forward-looking statements. For a discussion of
these and other risks that could cause such differences and that
may affect the realization of forward-looking statements, please
refer to the "Special Note On Forward-looking Statements" and "Risk
Factors" in the Company's Annual Report on Form 20-F and other
filings with the Securities and Exchange Commission (SEC).
Investors and security holders are urged to read these documents
free of charge on the SEC's web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
Investor Contacts
Vivian
Cervantes
PCG Advisory
646-863-6274
vivian@pcgadvisory.com
Meirav Gomeh-Bauer
+972-54-4764979
Meirav@bauerg.com
View original
content:http://www.prnewswire.com/news-releases/check-cap-announces-advancement-in-ge-healthcare-manufacturing-collaboration-300566769.html
SOURCE Check-Cap Ltd.